Charles Schwab Investment Management Inc Trevi Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 107,707 shares of TRVI stock, worth $320,966. This represents 0.0% of its overall portfolio holdings.
Number of Shares
107,707
Previous 107,707
-0.0%
Holding current value
$320,966
Previous $144,000
157.64%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
79Shares Held
50.5MCall Options Held
2.2KPut Options Held
600-
Nea Management Company, LLC Timonium, MD11.4MShares$33.9 Million2.75% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$22 Million1.34% of portfolio
-
Rubric Capital Management LP New York, NY5.56MShares$16.6 Million0.65% of portfolio
-
Viking Global Investors LP4.4MShares$13.1 Million0.06% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$10.2 Million1.01% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $174M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...